➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Express Scripts
Colorcon
Moodys

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

GAMUNEX-C Drug Profile


Email this page to a colleague

« Back to Dashboard

Summary for Tradename: GAMUNEX-C
Patents:4
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for GAMUNEX-C
Recent Clinical Trials for GAMUNEX-C

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Baylor College of MedicinePhase 1
University of WashingtonPhase 2
Grifols Biologicals, LLCPhase 2

See all GAMUNEX-C clinical trials

Patent Text Search: US Patents for GAMUNEX-C

These patents were identified by searching patent claims

Supplementary Protection Certificates for GAMUNEX-C

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1790003-6 Sweden   Get Started Free PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF AND DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE; REG. NO/DATE: EU/1/14/967 20141121
CR 2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
2016/061 Ireland   Get Started Free PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119
2015C/058 Belgium   Get Started Free PRODUCT NAME: COBICISTAT; AUTHORISATION NUMBER AND DATE: EU/1/13/830/001
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
Boehringer Ingelheim
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.